Frank Clyburn: Thank you, Glenn. I am tremendously proud of the work our teams at IFF have accomplished in the last quarter, as we remain laser-focused on developing innovative solutions and exceeding the expectations of our customers around the world. As you can see from our outlook, though we are moving into Q4 with caution, I am confident as we have demonstrated time and again and our global team's ability, to navigate even the most complex environments. As Glenn said, we are closely monitoring shifts in the market to effectively address any emerging challenge. We remain intensely focused on controlling the controllable, through the year-end and we continue to work with our customers to surgically implement pricing actions, meet or accelerate our productivity and portfolio optimization objectives, continue to delever our balance sheet and focus on driving profitable growth. As you know, we have made significant progress this year to strengthen our business and become more efficient. By leveraging our strong foundation and being laser-focused on our growth initiatives, I am confident in IFF's ability to be resilient and drive long-term value creation regardless of the market environment. Before I open the call up to questions, I would like to share official details about our upcoming Investor Day, which will be held on Wednesday, December 7 in New York City. We are excited to host this event and share more about the opportunities ahead for IFF including how we will capitalize on our leadership position, innovate for our customers, generate strong productivity and grow our business for the future. We hope you will all join us, and we look forward to seeing you there for what promises to be an engaging interactive and informative experience. Registration links for the in-person live event, have been sent out, but if you have not received one or have questions, please feel free to reach out to our Investor Relations department. This will also be webcasted broadly for those that cannot travel to New York City. With that, I would like to open up the call for questions.
Frank Clyburn: Hey, Mark, good morning. A couple of things that I wanted to highlight. You are correct. We are in the fourth quarter assuming volumes do decelerate versus the Q3 number that we just posted. And it's really two factors and I'll give you where the areas that are a focus for us right now what we're seeing. I'll start with our health business under the Health & Biosciences division, Mark. In health and I signaled this I think even earlier in the quarter, we are seeing both end-market demand slow as consumers are making choices between probiotics dietary supplements. So we are seeing some slowing end-market use in health and we are also seeing destocking in that business in particular in North America. And we expect that to continue through the fourth quarter as also well in Europe. So that's what we're seeing in our health businesses. And we went through the quarter, Mark. We did see July down. We saw August come back. September was down. And as we now started to see in October, we're seeing a similar trend of the deceleration I mentioned in that business. In Ingredients under Nourish and we highlighted this on our prepared remarks, Mark, we are also seeing more inventory destocking is the primary aspect of what we're assuming will continue as we go into the fourth quarter. We also within the Ingredients business did make some trade-offs from a pricing perspective. We had some of our Protein Solutions business that was capacity-constrained, where we did increase price made some volume trade-offs to preserve some margin, but it's primarily destocking. So that is the main reason and we're also assuming in that business that will continue in the fourth quarter. As we go into '23, we're expecting at least in the first half moderate volume growth. We'll explain a lot more of what we're anticipating for '23 as we get to Capital Markets Day, Mark, but that's what hopefully gives you some color on what we're seeing in the business. The other thing, I would highlight though and I think it's an important reminder for us that, if you do take a step back over the two-year time period and we mentioned this through Q3, we are growing our volumes 4%. And we are still seeing good growth in particular in Scent and Pharma that we highlighted as well. So, the isolation that I highlighted is really primarily in those two areas, which is where we're anticipating seeing the deceleration continues as mentioned.
Frank Clyburn: And Gunther, this is Frank. With regards to the second part of your question about the lower volumes and strong price increases, we do not see it broadly, Gunther, that our pricing actions have impacted volume. In fact if you look at what's happening in the market, many of our peers are also increasing pricing. So we do not see that as an impact. In fact, we've also reached out to many of our customers and we've been doing this in concert obviously with them. And they have clearly signaled that we have not seen any share losses per se, Gunther because of our pricing actions. The one area that I did highlight is where we made a conscious trade-off was within our Ingredients business where we were capacity-constrained. We did increase price and made some volume trade-offs to preserve margins. So that is the one area that I would highlight. The other thing is with regards to what is the driver, primarily as mentioned, it is destocking for our business is what we're seeing Gunther. And that is -- the main driver is our customers are looking at year-end their inventory levels and wanting to obviously manage their working capital appropriately. So, that's really the driver. The last thing I will say though, with all of that, one of the things and we'll spend more time on the Capital Markets Day is we are looking at ways to really continue to build our commercial execution. How do we work with our customers to really bring the full portfolio of IFF forward increasing our market share with our key customers, regional customers and global customers as well as new customer acquisition? And I'll be spending some more time here at Capital Markets Day really talking about our plans in that area to focus on our aspirations for growth, Gunther. So, much more to come.
Frank Clyburn: Yes. Heidi, it's Frank. And as I highlighted, as we went through the quarter and in particular in September, Heidi, we did start to really see the destocking that I mentioned. And also, we are seeing that in the month of October. So, as we look at now for our forecast for this fourth quarter, we're obviously taking those most recent data points into consideration. And that is why we feel as though appropriately so we have guided to the top line sales that we've mentioned in our prepared remarks. The one thing I do want to take a step back though Heidi and do highlight though is we still are confident that for the full year growing the business, 9% to 10%, if you were excluding exchange, we feel as though is a very good overall performance. Like I said clearly, the fourth quarter is where we're seeing some challenges, and this is primarily due to our customers wanting to manage the inventory. And we think it's the prudent approach to take based on what we're seeing in the last couple of months end of Q3 and then as I mentioned in October.
Frank Clyburn: Yeah. So thanks Mike for the question. A couple of things. As I look at the total portfolio, one would say that overall we feel as though -- and going into a recession, we are very resilient when you look at our portfolio overall. If I start with Nourish, Mike clearly if you think about ingredients in the end markets of food and beverage, we should be very resilient there. Our Flavors segment is a resilient business and then also Food Design. So if you were to exclude some of the near-term challenges that we're talking about from an inventory destocking perspective, we think that our nearest division would be overall very resilient in recessionary times. If I look at the Scent business what is really interesting Mike is that the one area that we have thought would be more of a challenge in a recession would be Fine Fragrance. However, we are seeing really good growth in our Fine Fragrance business this year and our Scent business overall has continued to hang in there very well with overall good strong volume growth. As I look at Health & Biosciences, clearly, we think that holds up very well, also Mike. In particular, if you think about Cultures & Food Enzymes or Home & Personal Care business within Health & Biosciences, we think is a really good business and holds up during a recession. Obviously we've highlighted on this call, the challenges we're seeing in that health segment in the probiotic marketplace, but overall fairly resistant. And then clearly we see pharma as being very resilient in a recessionary period of time. With all of that said, as you mentioned, we do see some challenging headwinds on the horizon. That's something that we are obviously spending time as a team. We'll share much more on our 2023 outlook. But think of the overall business we feel very resilient across our different businesses Mark -- or Mike I should say, and it's something we will clearly spend a lot of time here at Capital Markets Day unpacking even more for you.
Frank Clyburn: Hi. This is Frank. I'll start. And we've highlighted our significant focus this year on our productivity initiatives which have primarily been in our operations group where we focused on our supply chain. We're focusing on really looking at economic profit as a key driver of our choices and decisions in our manufacturing operations group or logistics costs. So I would first start, that we have made really good progress in improved productivity. And I think Glenn highlighted that in his prepared remarks. With that said, as you go into an additional -- or a downturn one of the things that we are now looking at is our total cost base for IFF. So we are looking at ways to think about accelerating productivity beyond our manufacturing operations focus that you've heard us talk about and we highlighted on our second call. That's something that we are going to share much more Capital Markets Day. We do think there are ways to reduce our cost base and accelerate productivity, while also preserving two things. One our investment in innovation and two really also making sure we're continuing to focus on working with our customers to drive growth. So more to come at Capital Markets Day, but we do think we will be able to accelerate productivity as we head into 2023.
Frank Clyburn: Yes. The only thing I would add, Jonathan, I think it's important though that we do still continue to see our customers seeing, how important innovation is for the future. So as we engage with them and as Glenn mentioned, some of what we're seeing, some down-trading near-term, et cetera. But the fact is, we are still seeing very high engagement from our customers wanting to work with us, with regards to our pipeline new projects innovation, which we think is going to be very important for the future for us and going forward. So that's something that I just wanted to also make sure that is reinforced. We're not seeing a pullback of customers not wanting to innovate for their future growth. And that's something that we're focused on really helping them to deliver on. 
Frank Clyburn: So thank you everyone for joining our call. Hopefully, you can see and hear despite some of the near-term challenges, we are extremely excited about the future in front of us with IFF. We look forward to December 7 in our Investor Day in the next couple of weeks where we'll really spend time sharing with you our growth our aspiration from an innovation perspective, how we'll continue to drive productivity to be able to reinvest in the business and why I'm very excited about the future of IFF going forward. So look forward to seeing many of you in New York City on the 7th, and thank you for joining our call. 
Glenn Richter: Yes. Hey, good morning, Adam. Thanks very much for the question. Clearly, it has been more challenging than expected this year and that's principally been driven by our inventory balances. So, maybe, if I can actually even start back in the first of the year, you cited the $800 million. We began the year at $1 billion target. And since that, it's been a combination of incremental pricing/inflation that was outside of plan. That's costing us about $125 million. And in addition, there's another $200 million of additional inventories we expect to be at year-end. By the way, that's a reduction of about $100 million from where we are. We ended the third quarter with inventories up $600 million from the start of the year. That was a large -- about $200 million of that is basically based on raw material inflation. About $400 million is basically based on, as Frank had mentioned, building inventories for service levels. But importantly, basically demand has slowed down and we've ended up with higher inventory. So, again, that's about $200 million delta from our original target. We are fully confident, we're going to get that $200 million back. We expect to get that back targeted in the first half of next year and even targeting more. On top of that our business has slowed down and there's been some differences in terms of our tax payments, really a timing element for us. That's collectively about $150 million. So those adjustments get us to sort of north of $500 million. So its $1 billion, minus $200 million higher volume-related inventories about another $125 million related to inflation, about $150 million slightly softer earnings than previous outlook and in addition some timing on tax. So that's a little over $500 million. I would note as we mentioned in our script, within our free cash flow that reported, its a GAAP basis in terms of free cash flow, so take it directly from our cash flow statement. That includes deal-related and integration costs. That's very material for us this year, given the sale of our Microbial Control business. So all the transaction-related costs, number of items for the standup at set were basically paid for as part of the deal and some integration-related costs. So there's about $225 million this year, that's sort of in -- it will be netted against that $525 million. So on it's a reported basis, if you will. That's more than $300 million. But frankly the $200 million is really a charge against operating cash flow when it's really related to sales of businesses. It's a little bit of an apples and oranges. So I'd sort of point to maybe $500 million as the true sort of operating cash flow this year. Of the gaps this year, clearly, $200 million inventory will get back. I'd say taxes clearly timing of another $100 million. That gets us to north of a little bit $800 million. And over time, we would expect the incremental raw materials that are sitting in our inventory this year, we'd expect to get that back over time. And again, that's over $250 million from the start of the year. So over time, we expect that to reverse as well. So hopefully, that was helpful.
Glenn Richter: Hey, Mark, it's Glenn. Good morning. Relative to our longer-term objectives on cash flow, we're going to hold that to our Capital Markets Day. So we're less than a month away from that. We'll have a chance to actually discuss more specifically our longer-term targets. And then I'll turn it over to Frank to talk about some of the flow trends.
Glenn Richter: Yes, John, thanks for the question. Actually it's more related to the amount of goodwill and intangibles that are allocated to the business. So let me -- just by way of background as I'm sure you're well aware, we prior to the end of the quarter had about $25 million of goodwill and intangibles on our books. They were assigned to each of the four divisions. They're directly related to the acquisitions. And by definition, the majority of that is from the N&B acquisition. So that allocation is concentrated in H&B Pharma and somewhat Nourish, but Nourish obviously has legacy IFF business as well. H&B and Pharma do not, right? So, if you will, it's a heavy sort of burden in terms of the goodwill intangibles against those two businesses. For context about 45% prior to the write-down of goodwill and intangibles was sitting on the books of H&B. So that's point one. Point two is, you're required to do an annual test or if there's an event that suggests there may be an impairment have to do it within the year. The event largely is attributable to the interest rate environment. So the way you basically run the calculation is you basically do a discounted cash flow for each of the businesses, you do forward projections. The forward projections on the H&B business were brought down. Those were in part because of exchange rates. So, all the businesses actually have lower earnings because we have to use the current exchange rates. Part of it is slightly lower operating performance, but exchange rates played a meaningful role. But the most significant variable is the discount rate. As everyone's well aware, the interest rates are going up rapidly. So the discount rate we were required to use for the cash flow was materially higher than a year ago and that's what resulted in the $2.25 billion. We do note in our disclosures that we have about 10% cushion on Pharma. As you would expect that will be the second business that would be under scrutiny, just given the amount of goodwill intangibles sign to the business. It is less significant on a relative basis for Scent and Nourish, because you have the legacy IFF businesses, that don't carry the goodwill and the other intangible impact as much. So it's really -- to some extent, I'd say it's a minor reflection on the outlook of the business and more reflective of the interest rate environment and what we're experiencing from the exchange rate.
Glenn Richter: Good afternoon, Gunther. I'll actually start by talking about the inflationary environment. I think then Frank will probably pick it up to talk about pricing dynamics relative to volume. First of all, we are clearly seeing a deceleration environment relative to raw materials in the marketplace. So that's happening in certain commodities going forward. But let me kind of step back and talk about our overall outlook for 2023 in terms of three components. One logistics is actually looking very favorable flat to maybe slightly down. We are encouraged by an ease up of the supply chain, which is helping not only in terms of cost for freight, but in addition just making sure that we're able to deliver on time to our customers. So that's a plus. Energy is incredibly volatile as everybody knows. And it's very difficult to call that. What we have been doing with our customers as many have been doing is implementing direct surcharges or variable pricing that's tied to energy prices. So that will ebb and flow depending upon the market dynamic. And again, that's fairly consistent with what's happening with many players. That tends to be as you're well aware more concentrated in the European market globally in terms of the impact. And then as it relates to raws, we are seeing -- we're still seeing inflationary pressure. I would basically put that in three buckets where there are certain commodity groups that are impacted by the energy environment and/or supply chain so synthetics; chemicals as an example; pulp as an example. Secondarily, we're clearly seeing some roll-off on contractual pricing we had or hedging this year. So that's actually impacting. And while there are certain price commodity categories that are beginning to decline year-over-year, they represent some modest increases for us, such as soybean, palm oil, et cetera. And related to that, we are expecting next year's raw inflation to be about half of what we had this year, so call it, high single digits in terms of the impact. You are correct in pricing environment continues to tighten up. By definition with a slowdown in consumer, everyone's trying to be a little bit more thoughtful in terms of commodity prices would be passed through. We are about to go to market for 2023 pricing. We have spent a lot of energy being very surgical relative to what makes sense or customer in terms of pricing tied directly to what we're seeing in the marketplace. So we are -- again, it will be a much lower number versus what we have, but we are expecting another round of 2023 pricing actions to offset the residual raw materials. 
Glenn Richter: Hey, Anthony this is Glenn. Thanks for joining us. I'd say it's really difficult for us to predict. We do track very closely end-consumer demand. So what information we get from largely the scanner data; secondarily, obviously, in very extensive dialogues with our customers in terms of what they're doing. And as a byproduct, we do believe that destocking in addition to declining the end-consumer demand are the key contributors to what we're seeing. And of note as Frank had mentioned, we see it most pronounced in a couple of categories: one in protein solutions; second, in probiotics. And as you follow the end market and look at what some of the major CPG firms are reporting, they're double-digit drops in terms of the end market. And particularly as you think about probiotics, which had a big, big booms related to COVID and the value of these things it's understandable why we would see the decline. So point one is we believe that this is destocking end consumer. Point two relative to how long this will run, we really don't know. A number of our customers have communicated to us that they believe by year-end, they will have their inventories in place. That, of course, assumes they have a good crystal ball relative to where the consumer is going. Others have indicated that they believe that this may extend into the first and second quarter of next year. So we'll be providing more perspective at our Investor Day relative to our outlook on 2023, but we do -- we will ultimately be factoring potentially further destocking and slow down the consumer as we think about the outlook for our financial performance for next year. So appreciate the question.
Glenn Richter: Hey, Josh. Good morning. Yeah. We're very pleased by the progress that our Scent business is making. Two things are exhibited in the third quarter trend versus the first half of the year. One is, we are beginning to sort of normalize for price versus inflation. So there was another round of pricing year to sort of catch-up for what's been happening with raw materials. That has been implemented. So it's been extremely helpful relative to the gross margin performance, and we expect that to normalize into the first half of next year. But then secondarily, the team has also undertaken actions to continue to manage their costs very tightly. So you'll notice that their RSNA expenses, also showed improvement from the first half to the third quarter as well. So the team is smartly and on a paced manner implemented pricing maintaining volumes quite well and on top of that taking additional productivity actions to make sure they manage the bottom line, and had a nice currency-neutral year-over-year growth as a result of that. 
Glenn Richter: Hey, Chris, yeah, relative to logistics costs year-over-year pretty flattish to slightly down. So we've actually seen nice improvement in the global supply chain. As I mentioned previously, raws we still have pressure about half of what we've seen this year. So think about it as sort of high single digit on our total raw material cost. And that's a function of contracts rolling off. It's also a function of certain categories those driven by energy prices continue to see escalation in areas that are being affected by continued war in Ukraine and other global supply chain issues. So call it half of the rate of this year, still meaningful for us to basically go capture. And as a byproduct of that, not only do we need to be smart on our next round of pricing actions, but everything Frank had mentioned around managing our cost structure as a way to sort of offset those pressures as well.
Glenn Richter: Well, let me attempt to answer it in a couple of dimensions, Jonathan. Obviously, with the consumer under pressure from inflation, there is a visible movement from branded to private label. So that's happening both in Europe and the US, although more pronounced in Europe. We play across the customers that play in both spaces. So we serve both markets. In general, not all cases, but in general our margins are fairly consistent between branded and private label from the standpoint. So from that standpoint, while the consumer is moving across branded to private label generally, we hold up well relative to the shift of our business. The customer also will look at formulations and how do they think about saving money through reformulations, it's very constant. It actually happens in all environments, but it's more pronounced in this type of environment. So we work very closely with them in terms of helping them, reformulate products basically to take cost out and deliver the same solution for the consumer. The third thing, I would say relative to the behavior of consumer is and this is clearly happening in the marketplace is, while the consumer may still actually stay within branded oftentimes they will reduce dosage. So think about that as sort of less home and personal care products usage, or less fabric softener as an example. So that is another factor that's happening that affects our business, as well as the customers' business. But it may in essence, also result in sort of lower volumes in the marketplace as well. So, hopefully, that's helpful. 
Glenn Richter: Yes. Matt, one underlying factor relative to the quarter is how we're trying to correct manufacturing volumes to offset the decline in demand in order to address our cash flow and inventory problems. So as a result of that the production volumes in the third quarter for Nourish were dropped even more so than demand. So there's an absorption issue relative to that's hitting the business. So that does affect sort of the marginal flow-through of the dollar if you will. Also quarter-to-quarter there was some inflationary pressures like energy and some other things that were, sort of, not outside of the period per se in terms of kind of the effects. So it's a little bit hard to, sort of, normalize one quarter to another as being, sort of, an apples-to-apples. But the reduction in volumes in order to get our inventories down is a factor that's hitting our business collectively in Q3 and also in Q2. And it's more pronounced in Nourish and H&B we've seen a more pronounced volume decline. So that's a factor in that calculus you cited. 
